BioNexus Gene Lab (BGLC) Assets Average (2019 - 2026)

BioNexus Gene Lab's Assets Average history runs 8 years deep, the most recent figure standing at $9.1 million for Q1 2026.

• In Q1 2026, Assets Average fell 8.14% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (down 8.14% YoY), while the FY2025 annual figure was $9.8 million, down 9.83% from the prior year.
• Assets Average came in at $9.1 million for Q1 2026 at BioNexus Gene Lab, up from $8.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $11.4 million in Q4 2023 to a low of $8.0 million in Q2 2023.
• A 5-year average of $9.5 million and a median of $9.4 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average soared 38.64% in 2024 and decreased 23.01% in 2025, its largest moves.
• BioNexus Gene Lab's Assets Average stood at $8.3 million in 2022, then surged by 38.26% to $11.4 million in 2023, then declined by 6.28% to $10.7 million in 2024, then decreased by 21.26% to $8.4 million in 2025, then grew by 8.41% to $9.1 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $9.1 million, $8.4 million, and $8.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison